IMPACT OF IODINE-CONTAINING PUMPKIN OIL ON THE COURSE OF CARDIAC ISCHEMIA IN THE RESIDENTS OF ZAKARPATTYA REGION

Authors

  • BALINT LYUBOV Uzhgorod National University, biochemistry and pharmacology department, Uzhgorod, Ukraine
  • LARYSA ROSTOKA Uzhgorod National University, biochemistry and pharmacology department, Uzhgorod, Ukraine
  • IVAN TURIANICA Slovak Agricultural University, human nutrition department, Nitra, Slovakia
  • PETER CHLEBO Slovak Agricultural University, human nutrition department, Nitra, Slovakia
  • MARTINA CIZMAROVA Slovak Agricultural University, human nutrition department, Nitra, Slovakia
  • OLEG KULCICKY Institute for Gerontology of MedicineAcademyScience of Ukraine

Keywords:

cardiac ischemia, simvastatin, cholesterol, lipoproteins, iodinecontaining oil

Abstract

The purpose of the research was exploration of the impact of the conventional
treatment in combination with simvastatin and iodine-containing pumpkin oil
“Fortuna vita” on the values of lipid metabolism in cardiac ischemia patients
residing in the setting of iodine deficit. The patients were divided into 2 groups:
group 1– patients underwent conventional treatment with application of simvastatin
of 20mg/day during the whole course of observation; group 2 – same treatment in
combination with iodine-containing pumpkin oil “Fortuna vita” of 10ml/day, which
contains 200μg of organically combined iodine form. The level of total cholesterol,
triglycerides, high-density lipoprotein cholesterol (HDL cholesterol) and lowdensity lipoprotein cholesterol (LDL cholesterol) in serum, and aspartate
aminotransferase and alanine aminotrasferase in patients before treatment, after 10
days, and after 1 month of treatment was measured. It was determined, that
simvastatin is an effective and safe cholesterol-reducing preparation for cardiac
ischemia patients which results in reduction of cholesterol level by 18% and LDL by
23% in one month. A combination of simvastatin and iodine-containing pumpkin oil
appears more effective, probably because of potentiation of their effects, which also
facilitate growth of antiatherogenic HDL and consequently decrease the
atherogenicity coefficient. The general clinical state of both groups improved as a
result of the treatment, though more so for the patients treated in combination with
iodine-containing pumpkin oil. We are inclined to explain this fact by normalization
of iodine-thyroid status, and consequently, of the general metabolism of the patients
in the setting of ecologic iodine deficit because of iodine-containing fatty acids.

References

Ex: Armitage, J., 2007, The safety of statins in clinical practice, Lancet,

, 1781-1790.

Ex: Cholesterol Treatment Trialists’ Collaborators. Efficacy and safety of

cholesterol-lowering treatment: prospective meta-analysis of data from 90,056

participants in 14 randomised trials of statins, Lanset, 2005, 366, 1267-1278.

Ex: Dujovne, C.A., Harris, W.S., Altan, R. et al., 2000, Effect of

atorvastatin on hemorheologic-hemostatic parameters and serum fibrinogen levels

in hyperlipidemic patients, Amer. J. Cardiology, 85, 350-353.

Ex: Gotto, A.M., 2003, Dyslipidemia and Coronary Heart Disease, 242.

Ex: Moron, D.J., Fazio, S., Linton, M.F., 2000, Current perspectives on

statins, Circulation, 18, 207 – 213.

Ex: Pyorala, K., Ballantyne, CM, Gumbiner, B., et al., 2004, Reduction of

cardiovascular events by simvastatin in nondiabetic coronary heart diseasise

patients with and without the metabolic syndrome: subgroup analyses of the

Scandinavian Simvastatin Survival Study (4S), Diabetes Care, 27, 1735-40.

Ex: Turianiсa, I., Angelovicova, M., Rostoka, L.et al., 2007, Enviromental

iodine deficit and problems connected with it, Nitra, 211.

Ex: Аронов, Д.М., 2001, Каковы результаты лечения симвастатином

при длительном (более 10 лет) применении? Возникает ли толерантность к

симвастатину? Каковы плеотропные эффекты статином?, Лечащий врач, 1, 5-

Ex: В.Г.Руденко, 2008, Новые возможности использования омега-3

жирных кислот в клинической практике, Здоров’я України, 17(78), 55.

Ex: Коваленко В.М., 2007, Атеросклероз і асоційовані з ним хвороби

внутрішніх органів: загальна стратегія профілактики та етапність

спеціалізованого лікування, Серцево-судинний континуум: шляхи ефективних

втручань, Київ, 5-26.

Ex: Лутай, М.І., Лисенко, А.Ф., 2007, Статини у профілактиці

серцево-судинних ускладнень, Therapia.Український медичний вісник, 4, 39-

Ex: Метелица, В.И., 2002, Справочник по клинической фармакологии

сердечно- сосудистых средств, М.: Бином, 619.

Ex: Сіренко, Ю.М., Граніч, В.М., Сидоренко, П.І., Кушнір, С.М., 2008

Ефективність та безпечність аторвастатину у хворих на артеріальну

гіпертензію після інсульту, Артеріальна гіпертензія, 1, 48-50.

Ex: Туряниця, І.М., Ростока, Л.М., Балінт, Л.І., 2002, Харчова

добавка, Деклараційний патент на винахід № 49605 А від 03.01.2002 р., 9.

Ex: Туряниця, І.М., Ростока, Л.М., Балінт, Л.І., 2002 а, Харчова

добавка, Деклараційний патент на винахід №49606 А від 03.01.2002 р., 9.

Downloads

Published

2023-10-03